A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 04 Jun 2016 Results assessing effect of dupilumab on PROs published in the Journal of the American Academy of Dermatology.
- 14 Jan 2016 Results published in the Journal of the American Academy of Dermatology
- 07 Oct 2015 Results published online in the Lancet.